(2) 228 करोड़ रुपये की अनुमानित लागत पर संयंत्र का पुनरूद्धार ।

(ख) और (ग) एफ० सी० आई० ने जिसे स्वास्थ्य सर्वेक्षण रिपोर्ट के संदर्भ में अपने बोर्ड की सिफारिशें भेजने को कहा गया था, वर्तमान स्थल पर 837 करोड़ रुपये की अनुमानित लागत पर 900 टन प्रतिदिन अमोनिया और 1500 टन प्रतिदिन यूरिया की क्षमता वाले एक नये नेफथा पर आधारित संयंत्र स्थापित करने को वरीयता दी है । सरकार इस मामले में शीघ्र निर्णय लेने के लिये सभी संभव उपाय करेगी ।

Reduction of custom duty on Ceftazidine

3090. SHRI ABDUL SAMAD SIDDIQUI: Will the PRIME MINSTER be pleased to state:

(a) whether it is a fact that the customs duty on Ceftazidime was reduced in July, 1991 but the company did not pass on the benefit of duty reduction by selling indigenously produced formulations at a lower price;

(b) whether it is a fact that the imports of this drug are over-invoiced and after customs duty reduction of bulk drug, formulations prices were jacked up instead of being reduced;

(c) what are the details in this regard and the reasons for reducing customs duty without having cost benefit analysis; and

(d) what steps have been taken to set up a Cell to examine duty rationalisation proposals in his Ministry before duty concessions are granted to ensure that the benefit is passed on to the public?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) The custom duty on bulk drug 'Ceftazidime' was reduced in July, 91. However, the actual import at 0% duty took place only in November, 1991 after necessary amendment in the notification. Ceftazidime injection in the finished form were being imported at 0% custom duty and only after withdrawing custom duty on bulk drug Ceftazidime, the manufacture of Ceftazidime Injection has been started in the coutnry. On import of injection in finished form, admissible margin is 50% only, whereas on indigenously manufactured injection, from imported bulk drug, there is no such restriction. To check whether the benefit of custom duty has been passed on to the consumer, the data submitted by the company is under examination. Regarding overinvoicing of the bulk drug, there is no information with the Government. The custom duty on bulk drug was reduced with a view to encourage indigenous production of formulations instead of importing them and to save foreign exchange.

(d) There is no proposal to set up a separate cell to examine duty rationalisation proposals. Strengthning/reorganising the present administrative arrangement for monitoring the impact of custom duty concessions is under examination.

Returns in form 2-A

3091. SHRIMATI KAILASHPATI:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 380 given in the Rajya Sabha on the 30th April, 1992 and state:

(a) whether it is a fact that during 1991-92 only returns in Form 2-A were received in respect of 50 packs;

(b) if so, what are the names of companies which had submitted Form 2-A, names of products and details of packs and what was the extent of price increase for which details were received;

(c) whether it is also a fact that companies went on increasing the prices but did not submit the details;

(d) if so, the details of such instances which came to the notice of Government; and

(e) what steps are being taken to probe into the matter?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) The number of companies and number of packs being arge, the time and labour involved in the collection and compilation of this voluminous information will not be commensurate with the results likely to be achieved.

(c) to (e) Manufacturers of decontrolled formulations are free to revise their prices themselves. Instances warranting intervention come to the notice of the Government not only from the information submitted by the companies in various forms prescribed in DPCO, 1987, but also from the data available from other sources. However, as already mentioned in reply to Rajya Sabha Unstarred Question No. 1147 answered on the 7th May, 1992, the overall compliance by the companies in regard to furnishing of information in Form 2A has not been very satisfactory. However, efforts are on to improve the compliance.

Prices of bulk drugs

3092. SHRI NYODEK YONGGAM:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1945 given in the Rajya Sabha on 14th May, 1992 and state:

(a) whether it is a fact that DPCO 1987 provides for fixation of prices of bulk drugs on the basis of weighted average of the cost based prices of major producers;

(b) whether it is also a fact that in violation of this provision, prices were recommended by BICP and also accepted by Government;

(c) if so, what are the names of those drugs;

(d) whether it is also a fact that Government have fixed the prices of bulk drugs on the basis of 2/3rd cut off level to benefit of the producers:

(e) if so, names of such drugs, names of producers of each and price fixed for each; and

(f) whether it is a fact that this principle was rejected under DPCO, 1979?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir. However, under DPCO 1987 weighted average price for a bulk drug for the purpose of determining prices of formulations can be fixed where Government fixes more than one price for a bulk drug.

(b) No, Sir.

(c) Does not arise.

(d) to (f) The maximum sale price of a price controlled bulk drug is fixed by the Government in accordance with DPCO 1987, after making necessary enquiries in the matter and taking into account the production capability and efficiency of the major manufacturing units. This is done in order to maintain uninterrupted supplies of a bulk drug so that shortages may not occur and availability of formulations, at reaosnable prices which is the ultimate interest of the consumer is ensured.

Revision of prices of formulations

3093. SHRI NYODEK YONGGAM:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 139 given in Rajya Sabha on 9th July, 1992 and state:

(a) whether it is a fact that prices of formulations based on the imported bulk drugs which are under price control are revised on a *suo-motto* basis or as and when the manufacturers apply for the same;

(b) if so, when the prices of formulations based thereon of each were revised: